%0 Journal Article
%T Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma
%A Dinushi Weerasinghe
%A Jessica L. Smith
%A Jonathan J. D. Baird-Gunning
%A Matteo S. Carlino
%A Matthew Silsby
%A Steve Vucic
%A Yash Gawarikar
%J The Neurohospitalist
%@ 1941-8752
%D 2018
%R 10.1177/1941874418778957
%X Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management
%K Miller-Fisher syndrome
%K immunotherapy
%K melanoma
%K CTLA-4 receptor
%K PD-1 receptor
%U https://journals.sagepub.com/doi/full/10.1177/1941874418778957